Home Magazines Editors-in-Chief FAQs Contact Us

Retrospective analysis in in situ ductal carcinoma; 11 years of experience


Obstetrics & Gynecology International Journal
Bianchi F, Ramilo T, Camargo A, Elizalde P, Farah N, De Fazio B, Dallochio MP, Castaño R

Abstract

Objective: To describe our experience in the diagnosis, treatment and follow up of patients with ductal carcinoma in situ (DCIS).
Materials and methods: 953 breast carcinomas treated in the Mastology service of the Department of Gynecology and Obstetrics of the Hospital Aleman of Buenos Aires, between January 2004 and December 2014, are retrospectively analyzed.
206 biopsies (BRQ 25-mammotome 151-core biopsy 30) of ductal carcinomas in situ were identified, resulting after definitive pathological evaluation in 172 (18%) pure ductal carcinomas in situ of the total of 953 patients analyzed.
Results: 206 biopsies (BRQ 25-mammotome 151-core biopsy 30) of ductal carcinomas in situ were identified, resulting after definitive pathological evaluation in 172 (18%) pure ductal carcinomas in situ of the total of 953 patients analyzed. The imaging report in the total of the 206 patients showed microcalcifications in 80.1%. The diagnosis of carcinoma in situ was made in 181 (87%) patients by preoperative microinvasive procedures and in the remaining 25 (13%) patients by radiosurgical biopsy (BRQ). There was evidence of 18.8% underdiagnosis after microinvasive procedures. In our case series, 84.3% were GH3/GH2 while 15.7% were GH 1. When comparing the size of the surgical specimens and correlating it with the 34 cases of invasive and microinvasive carcinoma, it showed that 54.8% of invasion in those tumors greater than 30 mm, 50.4% in those that exceeded 21 mm and in no case in those less than 10 mm. 20% of multicentric lesions were associated with invasive tumor. Sentinel lymph node technique was performed in 23.8% patients in the first surgery, resulting negative in all cases. When evaluating radiation and hormonal treatment, radiotherapy was performed in 131 patients (85.6%) and hormonal treatment was performed in 75% of the patients. In the follow-up until December 2014, 11 relapses (5.23%) were recorded.
Conclusion: Our results are consistent with the international indexed literature in reference to diagnosis, treatment and recurrence rate pure of DCIS.

Keywords

ductal carcinoma, breast, mammography, ovarian cancer syndrome

Testimonials